Hypofractionated radiotherapy compared with conventionally fractionated radiotherapy to treat initial distant metastases in nasopharyngeal carcinoma: A multicenter, prospective, randomized, phase II trial

医学 鼻咽癌 粘膜炎 临床终点 危险系数 内科学 放射治疗 随机对照试验 置信区间 胃肠病学 前瞻性队列研究 化疗 外科
作者
Jian Liu,Bin Zhang,Yixin Su,Guanjie Qin,Xiangyun Kong,Yunyan Mo,Rongjun Zhang,Wei Jiang
出处
期刊:Radiotherapy and Oncology [Elsevier BV]
卷期号:187: 109815-109815 被引量:3
标识
DOI:10.1016/j.radonc.2023.109815
摘要

To investigate the safety and efficacy of hypofractionated plus chemotherapy in patients with initially distant metastatic nasopharyngeal carcinoma (mNPC).Between May 2014 and June 2020, 35 patients initially diagnosed with mNPC were enrolled on prospective trial. The enrolled patients were assigned randomly to receive either hypofractionated plus chemotherapy (HFRT) or conventionally fractionated radiotherapy plus chemotherapy (CFRT). 60 Gy over 25 fractions was administered to the HFRT group (n = 17) and 69.96 Gy over 33 fractions was administered to the CFRT group (n = 18), both groups five times each week.Progression free survival (PFS) comprised the primary endpoint. Overall survival (OS), locoregional relapse-free survival (LRRFS), distant metastasis-free survival (DMFS), and acute and late toxicity comprised the secondary endpoints.Twenty-eight patients (seven were excluded) were enrolled. The 2-year PFS was 33.3% (HFRT group) versus 30.0% (CFRT group) (stratified hazard ratio (HR):1.09; 95% confidence interval (CI): 0.45-2.65, P = 0.843). The 2-year OS was 66.7% (HFRT group) versus with 62.5% (CFRT group) (stratified HR, 0.88; 95% CI; 0.31-2.51, P = 0.806). All patients experienced acute grade 1 or 2, skin toxicity, oral mucositis, difficulty swallowing, xerostomia, but no acute grade 3 or 4 toxicities. All patients had grade 1 late xerostomia. Two patients experienced hearing loss in the HFRT group (one grade 1 and one grade 3), and three patients experienced grade 1 hearing loss in the CFRT group. One patient developed mucosal necrosis in the HFRT group.Improving the balance between severe late toxicities and local control by appropriately reducing the total dose but increasing the fractionated dose has marked clinical significance for those patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
zs发布了新的文献求助30
1秒前
吕峰完成签到,获得积分10
3秒前
Echo完成签到,获得积分10
4秒前
5秒前
sheep完成签到,获得积分10
5秒前
6秒前
pluto的应助被飞飞采纳,获得10
8秒前
冷艳的奇异果完成签到,获得积分10
8秒前
LUO发布了新的文献求助30
10秒前
11秒前
11秒前
11秒前
斯文败类的应助被zheng采纳,获得10
12秒前
阿努比斯的应助被小郭子采纳,获得100
12秒前
12秒前
zs完成签到,获得积分10
12秒前
ok完成签到,获得积分10
14秒前
梁林涛关注了科研通微信公众号
15秒前
无敌大流流完成签到,获得积分10
15秒前
科研通AI2S的应助被科研助理795采纳,获得10
16秒前
lishihao发布了新的文献求助10
16秒前
renpp822完成签到,获得积分10
16秒前
原儿发布了新的文献求助10
17秒前
18秒前
缥缈冰珍发布了新的文献求助10
18秒前
18秒前
19秒前
亦天凛发布了新的文献求助10
19秒前
19秒前
余香的应助被淼淼采纳,获得10
20秒前
21秒前
爆米花的应助被cjh采纳,获得10
21秒前
lllllllllll完成签到,获得积分10
21秒前
情怀的应助被研友_X89o6n采纳,获得10
22秒前
贝贝贝发布了新的文献求助10
22秒前
23秒前
23秒前
DXJ发布了新的文献求助10
23秒前
体贴明辉发布了新的文献求助10
24秒前
田永完成签到 ,获得积分10
24秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193079
求助须知:如何正确求助?哪些是违规求助? 9579384
关于积分的说明 21865064
捐赠科研通 7792635
什么是DOI,文献DOI怎么找? 3437158
关于科研通互助平台的介绍 2560661
邀请新用户注册赠送积分活动 2483960